Jiaxing'an Dikang Biotechnology Co., Ltd.

主要目的：评价ADC189片/颗粒治疗儿童流感受试者的安全性。 次要目的：（1）评价ADC189片/颗粒在儿童流感受试者中活性代谢产物ADC189-I07的药代动力学（PK）特征；并评估ADC189-I07暴露-效应关系。（2）评价ADC189片/颗粒治疗儿童流感受试者的有效性。（3）评价ADC189片/颗粒在儿童流感受试者中的耐药性。

主要研究目的:评价伊曲康唑胶囊对中国健康受试者单次口服ADC189后，体内ADC189及其主要代谢产物ADC189-I07药代动力学特征的影响。次要研究目的:评估联合服用伊曲康唑和ADC189片在中国健康受试者中的安全性。

This study aims to answer how repeat doses of itraconazole impact the pharmacokinetics, safety, and tolerability of single doses of ADC189 in healthy adults.
Participants in this study will complete screening assessments within 14 days before the first dose of ADC189. Participants will be admitted to the clinical pharmacology center (CPC) and complete 2 periods of treatments. On Day 1 and 26, each participant will receive a single oral dose of ADC189 (45mg), under fasting condition On Day 22, all participants will receive oral doses of itraconazole 200 mg (bid), after meal. From Day 23 to Day 25, and Day 26-D39, participants will receive itraconazole 200 mg(qd). Blood and safety assessments will continue for 336-hours after dosing on Day 1 and Day 26. Participants will receive a telephone follow-up on D47 (±3) days for a final visit.